Repositorio Dspace

Efficacy and safety of recombinant activated factor VII for secondary prophylaxis in patients with Glanzmann thrombasthenia

Mostrar el registro sencillo del ítem

dc.contributor.author García-Jaen, Pablo
dc.contributor.author Ferandez-Mosteirin, Nuria
dc.contributor.author Serrano, María-Luisa
dc.contributor.author Riesco, Susana
dc.contributor.author Aguilar, Carlos
dc.contributor.author Gabaldon, David
dc.contributor.author Kanaan-Leis, Sara
dc.contributor.author González-Prieto, Almudena
dc.contributor.author Portugal, Raquel
dc.contributor.author Mendoza, María-del-Carmen
dc.contributor.author Gilabert, Carmen
dc.contributor.author Hortal, Ana
dc.contributor.author Díaz-Ajenjo, Lorena
dc.contributor.author Lama-Villanueva, Ana
dc.contributor.author González-Galan, Alba-Mei
dc.contributor.author Sánchez-Fuentes, Ana
dc.contributor.author Benito, Rocío
dc.contributor.author Rivera-Pozo, José
dc.contributor.author González-Porras, José-Ramon
dc.contributor.author Bastida, José-María
dc.date.accessioned 2026-09-17T12:16:52Z
dc.date.available 2026-09-17T12:16:52Z
dc.date.issued 2026-05
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/28157
dc.description.abstract BACKGROUND: Glanzmann thrombasthenia (GT) is a rare inherited platelet disorder associated with recurrent and sometimes life-threatening bleeding. Recombinant activated factor VII (rFVIIa) is approved for treatment of bleeding episodes or surgical prophylaxis in patients with GT who are refractory or alloimmunized to platelet transfusions. However, evidence for its use as secondary prophylaxis remains scarce. OBJECTIVES: This study described the efficacy and safety of rFVIIa secondary prophylaxis in patients with GT and recurrent and uncontrolled bleeding despite standard therapy. METHODS: A multicenter, retrospective study of patients with GT included in the Spanish Registry of Patients with Inherited Platelet Disorders (RETPLAC) was performed. We evaluated bleeding severity using the International Society on Thrombosis and Haemostasis (ISTH) bleeding assessment tool (BAT) and calculated the annualized bleeding rate (ABR) before and during rFVIIa prophylaxis. RESULTS: Of the 37 patients with GT included in RETPLAC, 4 patients received regular rFVIIa prophylaxis due to recurrent severe bleeding. Median baseline ISTH-BAT score was 13.5 (IQR, 9.5-18), and median preprophylaxis ABR was 3 (IQR, 3-5.25). All patients received rFVIIa of 90 ?g/kg, 3 twice weekly and 1 monthly. The median prophylaxis duration was 7.5 months (IQR, 6.75-12). Prophylaxis led to a 57.1% overall reduction in ABR, with resolution of severe bleeding in 2 patients and reduction in frequency in the remaining 2. Three patients achieved transfusion independence. All patients showed improvement in hemoglobin and iron profile. No thrombotic or adverse events occurred. CONCLUSION: Secondary prophylaxis with rFVIIa may be an effective option in patients with GT and recurrent severe bleeding unresponsive to standard therapy. Prospective studies are necessary to optimize dosing schedules and define its role in secondary prophylaxis.
dc.language.iso eng
dc.publisher ELSEVIER
dc.rights Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internacional
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es *
dc.subject.mesh Adolescent
dc.subject.mesh Adult
dc.subject.mesh Female
dc.subject.mesh Humans
dc.subject.mesh Male
dc.subject.mesh Factor VIIa/adverse effects/therapeutic use/administration & dosage
dc.subject.mesh Hemorrhage/prevention & control/etiology/blood
dc.subject.mesh Recombinant Proteins/therapeutic use/adverse effects/administration & dosage
dc.subject.mesh Recurrence
dc.subject.mesh Registries
dc.subject.mesh Retrospective Studies
dc.subject.mesh Secondary Prevention/methods
dc.subject.mesh Spain
dc.subject.mesh Thrombasthenia/drug therapy/complications/blood/diagnosis
dc.subject.mesh Treatment Outcome
dc.title Efficacy and safety of recombinant activated factor VII for secondary prophylaxis in patients with Glanzmann thrombasthenia
dc.type info:eu-repo/semantics/article 
dc.identifier.pmid 42433599
dc.relation.publisherversion https://linkinghub.elsevier.com/retrieve/pii/S2475037926034503
dc.type.version info:eu-repo/semantics/publishedVersion 
dc.identifier.doi 10.1016/j.rpth.2026.106792
dc.journal.title RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS
dc.identifier.essn 2475-0379


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internacional Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internacional

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta